See more : Offcn Education Technology Co., Ltd. (002607.SZ) Income Statement Analysis – Financial Results
Complete financial analysis of PROCEPT BioRobotics Corporation (PRCT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of PROCEPT BioRobotics Corporation, a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Honz Pharmaceutical Co., Ltd. (300086.SZ) Income Statement Analysis – Financial Results
- WesCan Energy Corp. (WCE.V) Income Statement Analysis – Financial Results
- Motorola Solutions, Inc. (MTLA.DE) Income Statement Analysis – Financial Results
- Enphase Energy, Inc. (0QYE.L) Income Statement Analysis – Financial Results
- Korian (KORI.PA) Income Statement Analysis – Financial Results
PROCEPT BioRobotics Corporation (PRCT)
About PROCEPT BioRobotics Corporation
PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally-invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). The company also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. As of December 31, 2021, it had an install base of 130 AquaBeam Robotic Systems worldwide comprising 78 in the United States. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in Redwood City, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 136.19M | 75.01M | 34.47M | 7.72M | 6.17M |
| Cost of Revenue | 65.14M | 37.93M | 18.61M | 8.97M | 8.05M |
| Gross Profit | 71.05M | 37.09M | 15.87M | -1.26M | -1.89M |
| Gross Profit Ratio | 52.17% | 49.44% | 46.02% | -16.26% | -30.56% |
| Research & Development | 48.45M | 28.98M | 18.99M | 16.28M | 13.15M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 131.77M | 88.83M | 51.04M | 30.27M | 28.52M |
| Other Expenses | 0.00 | -203.00K | -154.00K | -25.00K | -46.00K |
| Operating Expenses | 180.22M | 117.81M | 70.03M | 46.55M | 41.67M |
| Cost & Expenses | 245.36M | 155.74M | 88.64M | 55.52M | 49.72M |
| Interest Income | 7.55M | 2.01M | 121.00K | 184.00K | 1.15M |
| Interest Expense | 4.00M | 5.18M | 5.81M | 5.26M | 724.00K |
| Depreciation & Amortization | 3.81M | 4.32M | 2.98M | 2.70M | 1.49M |
| EBITDA | -98.10M | -77.65M | -51.06M | -45.06M | -39.76M |
| EBITDA Ratio | -72.03% | -104.93% | -156.77% | -580.32% | -663.85% |
| Operating Income | -109.17M | -80.72M | -54.16M | -47.80M | -43.55M |
| Operating Income Ratio | -80.16% | -107.61% | -157.12% | -619.44% | -705.95% |
| Total Other Income/Expenses | 3.27M | -6.43M | -5.69M | -5.22M | 1.58M |
| Income Before Tax | -105.90M | -87.15M | -59.85M | -53.02M | -41.98M |
| Income Before Tax Ratio | -77.76% | -116.18% | -173.62% | -687.04% | -680.42% |
| Income Tax Expense | 0.00 | 6.43M | 2.53M | 5.24M | 678.00K |
| Net Income | -105.90M | -93.58M | -62.38M | -58.26M | -42.65M |
| Net Income Ratio | -77.76% | -124.76% | -180.96% | -754.89% | -691.41% |
| EPS | -2.24 | -2.11 | -1.43 | -1.35 | -0.99 |
| EPS Diluted | -2.24 | -2.11 | -1.43 | -1.35 | -0.99 |
| Weighted Avg Shares Out | 47.26M | 44.40M | 43.68M | 43.25M | 43.25M |
| Weighted Avg Shares Out (Dil) | 47.26M | 44.40M | 43.68M | 43.25M | 43.25M |
PROCEPT BioRobotics Corporation (PRCT) Q4 2023 Earnings Call Transcript
PROCEPT BioRobotics Corporation (PRCT) Q4 2023 Earnings Call Transcript
PROCEPT BioRobotics Reports Fourth Quarter and Full Year 2023 Results
SAN JOSE, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported financial results for the year ended December 31, 2023.
PROCEPT BioRobotics Corporation (PRCT) Expected to Beat Earnings Estimates: Should You Buy?
PROCEPT BioRobotics Corporation (PRCT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
3 Medtech Stocks Likely to Top Estimates This Earnings Season
Here are three stocks, GMED, GKOS and PRCT, which are expected to beat earnings estimates in the ongoing reporting cycle.
PROCEPT BioRobotics to Present at the 44th Annual TD Cowen Health Care Conference in Boston
SAN JOSE, Calif., Feb. 12, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced that members of management will present at the...
Strength Seen in PROCEPT BioRobotics Corporation (PRCT): Can Its 15.1% Jump Turn into More Strength?
PROCEPT BioRobotics Corporation (PRCT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
PROCEPT BioRobotics® Announces Preliminary Fourth Quarter Revenue of $43.3 million to $43.6 million
SAN JOSE, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported preliminary unaudited revenue for the quarter and...
PROCEPT BioRobotics to Present at the 35ᵗʰ Annual Piper Sandler Healthcare Conference in New York City
SAN JOSE, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced that members of management will present at the...
Wall Street Analysts Predict a 25.54% Upside in PROCEPT BioRobotics Corporation (PRCT): Here's What You Should Know
The mean of analysts' price targets for PROCEPT BioRobotics Corporation (PRCT) points to a 25.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an...
PROCEPT BioRobotics Corporation (PRCT) Q3 2023 Earnings Call Transcript
PROCEPT BioRobotics Corporation (PRCT) Q3 2023 Earnings Call Transcript
Source: https://incomestatements.info
Category: Stock Reports